The use of the tumor necrosis factor (TNF)‐α inhibitor etanercept in a small randomized, placebo‐controlled, double‐blind study to block low‐grade peripheral systemic inflammation in AD patients showed trends that favor etanercept compared to placebo 4. This evidence concerns the gene TNF and Alzheimer disease.